Detalhe da pesquisa
1.
Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
N Engl J Med
; 384(7): 630-642, 2021 02 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33596357
2.
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
Hum Reprod
; 39(3): 526-537, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38243752
3.
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
Lancet
; 399(10343): 2267-2279, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717987
4.
Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
Am J Obstet Gynecol
; 228(3): 320.e1-320.e11, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370871
5.
LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
Am J Obstet Gynecol
; 229(6): 662.e1-662.e25, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37666383
6.
Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials.
Gynecol Endocrinol
; 39(1): 2249107, 2023 Aug 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37634528
7.
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study.
BMC Musculoskelet Disord
; 18(1): 174, 2017 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28449657
8.
Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis.
Pharmacoepidemiol Drug Saf
; 22(10): 1107-14, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23857864
9.
A plain language summary of the long-term relugolix combination therapy study for uterine fibroids.
J Comp Eff Res
; 12(8): e230069, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37477173
10.
A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies.
Pain Manag
; 13(4): 205-211, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183454
11.
A Plain Language Summary to learn about relugolix combination therapy for the treatment of pain associated with endometriosis.
Pain Manag
; 13(11): 631-640, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37982388
12.
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.
Obstet Gynecol
; 139(6): 1070-1081, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35675604
13.
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
Obstet Gynecol
; 140(6): 920-930, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36357960
14.
Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab.
J Bone Miner Res
; 35(7): 1282-1288, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32163613
15.
Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial.
J Bone Miner Res
; 34(4): 626-631, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30601581
16.
Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years.
J Clin Endocrinol Metab
; 104(6): 2443-2452, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30759221
17.
Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment.
J Clin Endocrinol Metab
; 104(8): 3450-3461, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31125092
18.
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Lancet Diabetes Endocrinol
; 6(6): 445-454, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29631782
19.
Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.
J Clin Endocrinol Metab
; 103(7): 2498-2509, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29672714
20.
Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension.
J Bone Miner Res
; 32(7): 1481-1485, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28277603